Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD

Overview of attention for article published in Biomedicines, June 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#28 of 5,843)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 27 news stories from 27 outlets.

Stalicla SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for…

Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined…

Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined…

Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 23 additional news stories.